U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description

Terlipressin (Glypressin) is indicated for the treatment of bleeding oesophageal varices and in some countries for the treatment of hepato-renal syndrome type 1. It is a prodrug and is converted to the lysine vasopressin in the circulation after the N-triglycyl residue is cleaved by endothelial peptidases. This results in a ‘slow release’ of the vasoactive lysine vasopressin. Terlipressin exerts its action by activating V1a, V1b and V2 vasopressin receptors.

Approval Year

PubMed

PubMed

TitleDatePubMed
Hepatorenal syndrome in cirrhotic patients: terlipressine is a safe and efficient treatment; propranolol and digitalic treatments: precipitating and preventing factors?
2000 Oct
Inhibition of prostacyclin by indomethacin ameliorates the splanchnic hyposensitivity to glypressin in haemorrhage-transfused common bile duct-ligated rats.
2001 Feb
Vascular hyporesponsiveness in cirrhosis - many facets of a common problem!
2001 Feb
Terlipressin for treating intraoperative hypotension: can it unmask myocardial ischemia?
2001 Jul
Life, death, and varices.
2001 Nov
Hemodynamic effects of terlipressin (a synthetic analog of vasopressin) in healthy and endotoxemic sheep.
2001 Sep
Drug therapy for portal hypertension.
2001 Sep
New method of cardiac output measurement using ultrasound velocity dilution in rats.
2001 Sep
Update on treatment of variceal hemorrhage.
2002
Management of esophageal varices.
2002
Emergency sclerotherapy versus medical interventions for bleeding oesophageal varices in cirrhotic patients.
2002
Hemodynamic effects of a combination of octreotide and terlipressin in patients with viral hepatitis related cirrhosis.
2002 Apr
Terlipressin-ephedrine versus ephedrine to treat hypotension at the induction of anesthesia in patients chronically treated with angiotensin converting-enzyme inhibitors: a prospective, randomized, double-blinded, crossover study.
2002 Apr
Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.
2002 Apr
Terlipressin for norepinephrine-resistant septic shock.
2002 Apr 6
Update on ascites and hepatorenal syndrome.
2002 Aug
Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study.
2002 Feb
Effects of serotonin and vasopressin on cortisol production from an adrenocortical tumor causing subclinical Cushing's syndrome.
2002 Nov
Terlipressin for acute esophageal variceal hemorrhage.
2003
Terlipressin and albumin for the hepatorenal syndrome.
2003 Apr
Terlipressin and albumin combination treatment in hepatorenal syndrome.
2003 Dec
Portal hypertensive bleeding.
2003 Dec
Effects of the V1a vasopressin agonist F-180 on portal hypertension-related bleeding in portal hypertensive rats.
2003 Dec
Terlipressin dose response in healthy and endotoxemic sheep: impact on cardiopulmonary performance and global oxygen transport.
2003 Feb
Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial.
2003 Feb
Patient with a sudden drop in blood pressure.
2003 Jan
Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats.
2003 Jan
Successful resuscitation of serious bupivacaine intoxication in a patient with pre-existing heart failure.
2003 Jan
[Vasodilatory septic shock refractory to catecholamines: is there a role for terlipressin?].
2003 Jul
[Acute upper gastrointestinal hemorrhage. Diagnosis and management].
2003 May
Terlipressin infusion in catecholamine-resistant shock.
2003 Oct
[Vasoconstrictive Therapies for Bleeding Esophageal Varices and their Mechanisms of Action].
2003 Oct
[Vasopressin and its analogues in the therapy of shock].
2004
Vasopressors for shock.
2004
[Acute upper gastrointestinal variceal bleeding: vasoactive agents].
2004 Apr
Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock.
2004 Apr
Effects of terlipressin on systolic pulmonary artery pressure of patients with liver cirrhosis: an echocardiographic assessment.
2004 Aug 1
Systemic, portal and renal effects of terlipressin in patients with cirrhotic ascites: pilot study.
2004 Jan
Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study.
2004 Jan
Pressure or flow?
2004 Jun
Clinical review: influence of vasoactive and other therapies on intestinal and hepatic circulations in patients with septic shock.
2004 Jun
[Refractory hypotension during anesthesia in a patient treated with angiotensin receptor blockers].
2004 Jun-Jul
Terlipressin bolus induces systemic vasoconstriction in septic shock.
2004 Mar
Terlipressin for catecholamine-resistant septic shock in children.
2004 Mar
Effect of terlipressin on blood volume distribution in patients with cirrhosis.
2004 May

Sample Use Guides

In Vivo Use Guide
The maximum dose is 1.7 mg given every 4 hours for up tp 48 hours (bleeding oesophageal varices) or every 6 hours for up to 2 weeks (hepatorenal syndrome, type 1).
Route of Administration: Intravenous
In Vitro Use Guide
Isolated perfused mesenteric arteries of portal vein ligated and sham-operated rats were contracted by methoxamine (3 nmol-3 mumol) and then treated with nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester (100 microM), terlipressin or the selective V2 receptor agonist desmopressin (each 0.5 uM). Terlipressin alone reduced and in combination with NG-nitro-L-arginine methyl ester abolished the difference in reactivity to methoxamine between the portal vein ligated and sham-operated groups.
Name Type Language
TERLIPRESSIN
DASH   INN   MART.   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
GLY-GLY-GLY-CYS-TYR-PHE-GLN-ASN-CYS-PRO-LYS-GLY-NH2 (4-9 DISULFIDE)
Common Name English
TERLIPRESSIN [INN]
Common Name English
GLYCYLPRESSIN
Common Name English
N-(N-(N-GLYCYLGLYCYL)GLYCYL)-8-L-LYSINEVASOPRESSIN
Common Name English
TERLIPRESSIN [MART.]
Common Name English
TERLIPRESSIN [USAN]
Common Name English
TERLIPRESSIN [WHO-DD]
Common Name English
TERLIPRESSIN ACETATE [JAN]
Common Name English
TERLIPRESSIN [MI]
Common Name English
GLYCYLGLYCYLGLYCYL(8-L-LYSINE)VASOPRESSIN
Common Name English
VASOPRESSIN, N-(GLYCYLGLYCYLGLYCYL)-8-L-LYSINE-
Common Name English
GLYPRESSIN
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 580417
Created by admin on Mon Oct 21 20:13:36 UTC 2019 , Edited by admin on Mon Oct 21 20:13:36 UTC 2019
FDA ORPHAN DRUG 534216
Created by admin on Mon Oct 21 20:13:36 UTC 2019 , Edited by admin on Mon Oct 21 20:13:36 UTC 2019
FDA ORPHAN DRUG 11785
Created by admin on Mon Oct 21 20:13:36 UTC 2019 , Edited by admin on Mon Oct 21 20:13:36 UTC 2019
WHO-VATC QH01BA04
Created by admin on Mon Oct 21 20:13:36 UTC 2019 , Edited by admin on Mon Oct 21 20:13:36 UTC 2019
FDA ORPHAN DRUG 191804
Created by admin on Mon Oct 21 20:13:36 UTC 2019 , Edited by admin on Mon Oct 21 20:13:36 UTC 2019
WHO-ATC H01BA04
Created by admin on Mon Oct 21 20:13:36 UTC 2019 , Edited by admin on Mon Oct 21 20:13:36 UTC 2019
NCI_THESAURUS C80212
Created by admin on Mon Oct 21 20:13:36 UTC 2019 , Edited by admin on Mon Oct 21 20:13:36 UTC 2019
Code System Code Type Description
ChEMBL
CHEMBL2135460
Created by admin on Mon Oct 21 20:13:36 UTC 2019 , Edited by admin on Mon Oct 21 20:13:36 UTC 2019
PRIMARY
WIKIPEDIA
TERLIPRESSIN
Created by admin on Mon Oct 21 20:13:36 UTC 2019 , Edited by admin on Mon Oct 21 20:13:36 UTC 2019
PRIMARY
ECHA (EC/EINECS)
238-680-8
Created by admin on Mon Oct 21 20:13:36 UTC 2019 , Edited by admin on Mon Oct 21 20:13:36 UTC 2019
PRIMARY
NCI_THESAURUS
C77387
Created by admin on Mon Oct 21 20:13:36 UTC 2019 , Edited by admin on Mon Oct 21 20:13:36 UTC 2019
PRIMARY
RXCUI
57048
Created by admin on Mon Oct 21 20:13:36 UTC 2019 , Edited by admin on Mon Oct 21 20:13:36 UTC 2019
PRIMARY RxNorm
CAS
14636-12-5
Created by admin on Mon Oct 21 20:13:36 UTC 2019 , Edited by admin on Mon Oct 21 20:13:36 UTC 2019
PRIMARY
MERCK INDEX
M10580
Created by admin on Mon Oct 21 20:13:36 UTC 2019 , Edited by admin on Mon Oct 21 20:13:36 UTC 2019
PRIMARY Merck Index
MESH
C012078
Created by admin on Mon Oct 21 20:13:36 UTC 2019 , Edited by admin on Mon Oct 21 20:13:36 UTC 2019
PRIMARY
EVMPD
SUB10927MIG
Created by admin on Mon Oct 21 20:13:36 UTC 2019 , Edited by admin on Mon Oct 21 20:13:36 UTC 2019
PRIMARY
EPA CompTox
14636-12-5
Created by admin on Mon Oct 21 20:13:36 UTC 2019 , Edited by admin on Mon Oct 21 20:13:36 UTC 2019
PRIMARY
INN
5114
Created by admin on Mon Oct 21 20:13:36 UTC 2019 , Edited by admin on Mon Oct 21 20:13:36 UTC 2019
PRIMARY
PUBCHEM
72081
Created by admin on Mon Oct 21 20:13:36 UTC 2019 , Edited by admin on Mon Oct 21 20:13:36 UTC 2019
PRIMARY
DRUG BANK
DB02638
Created by admin on Mon Oct 21 20:13:36 UTC 2019 , Edited by admin on Mon Oct 21 20:13:36 UTC 2019
PRIMARY